title: Local injection of adalimumab for perianal Crohn's disease: better than infliximab?
authors.forename: G
authors.initials: G
authors.lastname: Poggioli
authors.forename: S
authors.initials: S
authors.lastname: Laureti
authors.forename: F
authors.initials: F
authors.lastname: Pierangeli
authors.forename: P
authors.initials: P
authors.lastname: Bazzi
authors.forename: M
authors.initials: M
authors.lastname: Coscia
authors.forename: L
authors.initials: L
authors.lastname: Gentilini
authors.forename: P
authors.initials: P
authors.lastname: Gionchetti
authors.forename: F
authors.initials: F
authors.lastname: Rizzello
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D001004:Anus Diseases / Q000188:drug therapy* / Q000473:pathology; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D000069285:Infliximab; D007267:Injections; D011379:Prognosis; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab